Latest version offers a streamlined site-centric experience to simplify relationships with study sponsors.
Veeva Systems has announced the newest release of Veeva Site Connect. New capabilities of the solution are headlined by a streamlined site-centric experience that will simplify and standardize site-sponsor relationships.1
The solution offers sponsors and sites a single place to collaborate, automating information flow throughout the lifecycle of a clinical trial. Information flow includes protocols, safety reports, payment letters, and more.
New features of Veeva Site Connect include:
“By standardizing how information is shared across all sites in one application with Veeva Site Connect, we aim to save time and effort that can be focused on treating patients,” a clinical operations excellence leader at a top 20 biopharma said in a press release. “Our goal is to eliminate manual handoffs and inefficiencies for faster site start-up, more efficient monitoring, and simplified study closeout.”
Veeva Site Connect is part of Veeva Clinical Platform, which is the provider’s complete solution for patients, sites, and sponsors. According to Veeva, seven of the top 20 biopharmas have already adopted Site Connect.
“I would be ecstatic if all our sponsors use Veeva Site Connect. It gives sites a much more efficient way to collaborate with sponsors, maintain regulatory compliance, and get critical therapies to patients faster,” Alisha Garibaldi, CEO, Skylight Health Research, said in the press release. “The less time we spend doing administrative work in systems, the more time we have to execute trials and help patients.”
Marta Jureczko-Hinzmann, head of global clinical solution services at AstraZeneca added, “By implementing Veeva Site Connect for our safety letter distribution process, we anticipate achieving a significant reduction in manual processing while enhancing oversight and compliance. Sharing safety letters across all sites globally within a single application will allow us to harmonize the entire process across the company and optimize how we allocate valuable resources.”
This announcement from Veeva comes just days before its R&D Quality Summit which will be taking place in Boston, MA, September 9-10.
1. Major Release of Veeva Site Connect Streamlines Clinical Trial Execution for Sites and Sponsors. News release. Veeva Systems. September 5, 2024. Accessed September 5, 2024. https://www.veeva.com/resources/major-release-of-veeva-site-connect-streamlines-clinical-trial-execution-for-sites-and-sponsors/
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.